However, mice treated via intracerebroventricular (i.c.v.)injection displayed localized FKBP12 degradation in the brain, potentially expanding the use of PROTACs to GBM as well as other brain diseases including neurodegenerative disorders such as Alzheimer’s disease. This evidence concerns the gene FKBP1A and Alzheimer disease.